View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 10, 2022

BD signs deal with Labcorp for companion diagnostics development

The companies will combine their capabilities to advance flow cytometry as an essential CDx modality for cancer.

Becton, Dickinson and Company (BD) and Labcorp have signed a collaboration agreement for the development of flow cytometry-based companion diagnostics (CDx).

Under the collaboration deal, both companies will develop, produce and commercialise CDx that will match patients with treatments for cancer and other diseases.

BD and Labcorp Drug Development will jointly work on flow cytometry-based CDx opportunities with pharmaceutical partners.

Combining their individual capabilities, including an end-to-end solution, they will also develop CDx for the pharmaceutical industry.

The companies’ joint offering will include the development of exploratory panels, US Food and Drug Administration (FDA) approval of diagnostic and manufacturing, and distribution of in vitro diagnostic (IVD) kits.

BD Biosciences president Puneet Sarin said: “In the companion diagnostic landscape, there is a clear and urgent need for high sensitivity and multiplexing capabilities, and that is where flow cytometry can help.

“BD and our dedicated CDx team are uniquely positioned to advance flow cytometry as a companion diagnostic tool, and we are pleased to join forces with Labcorp to pursue opportunities with the pharmaceutical industry to develop new companion diagnostics that can potentially improve patient outcomes and drive us forward in advancing the world of health.”

The company stated that the selection of optimal first-line treatment for cancer patients using CDx ensures better outcomes as well as saving cost and time.

The existing CDx tests commonly include polymerase chain reaction (PCR), immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH), or next-generation sequencing (NGS) and imaging. Meanwhile, flow cytometry is said to be an emerging technology in this area.

Labcorp Drug Development chief scientific officer Dr Bill Hanlon said: “Flow cytometry is a trusted and powerful tool for analysing cells to better understand disease, and it has tremendous untapped potential as a companion diagnostic in oncology and other therapeutic areas.”

Recently, BD reported a 0.7% increase in revenue in the third quarter of the fiscal year 2022.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network